Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Foreword
- Acknowledgments
- 1 Introduction
- 2 Culture and psychopathology
- 3 Culture and ethnicity in psychopharmacotherapy
- 4 Ethnic differences in psychotropic drug response and pharmacokinetics
- 5 Pharmacogenetics of ethnic populations
- 6 Variation in psychotropic responses in the Chinese population
- 7 Variation in psychotropic responses in the Hispanic population
- 8 Identifying inter-ethnic variations in psychotropic response in African Americans and other ethnic minorities
- 9 Complementary medicines in mental disorders
- 10 Cultural factors and the use of psychotropic medications
- 11 Outpatient prescribing practices in Asian countries
- 12 Psychiatric inpatient psychotropic prescribing in East Asia
- 13 Pharmaco-economic implications for Asia and other economically disadvantaged countries
- 14 Integrating theory, practice and economics in psychopharmacology
- 15 Research directions in ethno-psychopharmacology
- Index
- References
8 - Identifying inter-ethnic variations in psychotropic response in African Americans and other ethnic minorities
Published online by Cambridge University Press: 22 August 2009
Book contents
- Frontmatter
- Contents
- List of figures
- List of tables
- List of contributors
- Foreword
- Acknowledgments
- 1 Introduction
- 2 Culture and psychopathology
- 3 Culture and ethnicity in psychopharmacotherapy
- 4 Ethnic differences in psychotropic drug response and pharmacokinetics
- 5 Pharmacogenetics of ethnic populations
- 6 Variation in psychotropic responses in the Chinese population
- 7 Variation in psychotropic responses in the Hispanic population
- 8 Identifying inter-ethnic variations in psychotropic response in African Americans and other ethnic minorities
- 9 Complementary medicines in mental disorders
- 10 Cultural factors and the use of psychotropic medications
- 11 Outpatient prescribing practices in Asian countries
- 12 Psychiatric inpatient psychotropic prescribing in East Asia
- 13 Pharmaco-economic implications for Asia and other economically disadvantaged countries
- 14 Integrating theory, practice and economics in psychopharmacology
- 15 Research directions in ethno-psychopharmacology
- Index
- References
Summary
Introduction
The United States is becoming more diverse, ethnically and culturally. This process is happening primarily through immigration and also to some extent from differential birth rates of various ethnic groups. Over a third of today's Americans are considered ethnic minorities. Currently Hispanics and African Americans each make up about 15% of the population. It is anticipated that individuals of European ancestry will become less than a majority in 2050 (US Census, 2000).
These population changes have important implications for pharmacotherapy. It is now widely accepted that genetic differences between the various ethnic groups are quite small and probably less than individual differences. The recent experience with the newly approved congestive heart failure medication, BiDil, suggests that even minor differences can have significant pharmacological consequences.
The concept for BiDil developed from studies conducted in veterans administration hospitals on the effectiveness of the combination of two older drugs, hydralazine and isosorbide dinitrate, on congestive heart failure. Neither drug had an indication for congestive heart failure. No significant effect was seen in these studies on the general veteran population with congestive heart failure. However, a post-hoc analysis showed that the combination agents were effective for the African Americans in the study (Carson et al., 1999). A subsequent larger study, the African American Heart Failure Trial confirmed the efficacy of the combination medication in a patient population with congestive heart failure that was exclusively African American (Taylor et al., 2004).
- Type
- Chapter
- Information
- Ethno-psychopharmacologyAdvances in Current Practice, pp. 111 - 117Publisher: Cambridge University PressPrint publication year: 2008
References
(2003). Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. J. Natl. Med. Assoc., 95, 37–44.Google Scholar
(2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3, 229–43.CrossRefGoogle Scholar
, , et al. (1999). Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J. Card. Fail., 5, 178–87.CrossRefGoogle Scholar
, , et al. (1999). Attitudes and beliefs of African-Americans toward participation in medical research. J. Gen. Int. Med., 14, 537–46.CrossRefGoogle Scholar
, , , et al. (2005). The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry, 66, 15–27.CrossRefGoogle Scholar
& (2006). Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am. J. Psychiatry, 163, 1697–704.CrossRefGoogle Scholar
, & (1994). Race and tardive dyskinesia among outpatients at a CMHC. Hosp. Comm. Psychiatry, 45, 38–42.CrossRefGoogle Scholar
, , . et al. (2006). African-American community attitudes and perceptions toward schizophrenia and medical research: an exploratory study. J. Natl. Med. Assoc., 98, 18–27.Google Scholar
, & (1995). Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch. Gen. Psychiatry, 52, 756–65.CrossRefGoogle Scholar
& (2006). Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatry Serv., 57, 123–6.CrossRefGoogle Scholar
(1986). Racial and ethnic factors in psychiatric research. Hosp. Comm. Psychiatry, 37, 50–4.CrossRefGoogle Scholar
Lawson, W. B. (1990). Biological markers in neuropsychiatric disorders: racial and ethnic factors. In E. Sorel, ed., Family, Culture, and Psychobiology. New York: Levas.
Lawson, W. B. (2000). Issues in the pharmacotherapy of African American. In P. Ruiz, ed., Review of Psychiatry. Washington DC: American Association Press, Vol. 19(4), pp. 37–53.
(2001). Biological differences in depression and anxiety across races and ethnic groups. J. Clin. Psychiatry, 62(13), 13–19.Google Scholar
Lindamer, L., Lacro, J. P. & Jeste, D. V. (1999). Relationship of ethnicity to the effects of antipsychotic medication. In J. M. Herrara, W. B. Lawson and J. J. Sramek, eds., Cross Cultural Psychiatry. Sussex: John Wiley & Sons.
, , et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet., 78, 804–14.CrossRefGoogle Scholar
, , et al. (2000). Racial variation in antidepressant treatment in a Medicaid population. J. Clin. Psychiatry, 61, 16–21.CrossRefGoogle Scholar
& (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry, 50, 723–33.CrossRefGoogle Scholar
, & (2005). A pilot study of racial differences in erythrocyte lithium transport. Am. J. Psychiatry, 137, 120–1.Google Scholar
& (2005). Cross-cultural psychopharmacology: a current clinical perspective. Psychiatry Serv., 56, 31–3.CrossRefGoogle Scholar
& (2005). BiDil: Race medicine or race marketing?Health Affairs, web exclusive (http://content.healthaffairs.org/cgi/content/abstract/hlthaff.w5.455).CrossRefGoogle Scholar
, , et al. (2002). Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics, 12, 235–40.CrossRefGoogle Scholar
, & (1996). Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Serv., 47, 282–6.CrossRefGoogle Scholar
, & (2000). Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies. J. Natl. Med. Assoc., 92, 563–72.Google Scholar
, & (2002). Racial differences in factors that influence the willingness to participate in medical research studies. Ann. Epidemiol., 12, 248–56.CrossRefGoogle Scholar
, , , et al. (1995). Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol. Psychiatry, 37, 325–30.CrossRefGoogle Scholar
, , et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry, 163, 611–22.CrossRefGoogle Scholar
, Ziesche, S., Yancy, C. et al. (2004). Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. N. Engl. J. Med., 351, 2049–57.CrossRefGoogle Scholar
, , et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry, 154, 457–65.CrossRefGoogle Scholar
Tran, P. T., Lawson, W. B., Andersen, S. et al. (1999). Treatment of the African American patient with novel antipsychotic agents. In J. M. Herrara, W. B. Lawson and J. J. Sramek, eds., Cross-Cultural Psychiatry. Sussex: John Wiley & Sons.
, , et al. (2006). STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am. J. Psychiatry, 163, 28–40.CrossRefGoogle Scholar
US Census (2006). Available at: http://www.census.gov/ [Accessed March 6, 2006].
US Department of Health and Human Services (2001). Mental health: culture, race, and ethnicity – a supplement to mental health: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration.
US Food and Drug Administration (2005). FDA approves BiDil heart failure drug for Black patients. Press Release, June 23, 2005. www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html [Accessed October 4, 2005].
, , et al. (2006). What happened to lithium? Antidepressant augmentation in clinical settings. Am. J. Psychiatry, 163, 1219–25.CrossRefGoogle Scholar
, , et al. (2006). Are racial and ethnic minorities less willing to participate in health research?PLoS Med., 3, e19.Google Scholar
- 4
- Cited by